Journal article

DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.

Verena Sailer, Ulrike Sailer, Emma Grace Bawden, Romina Zarbl, Constanze Wiek, Timo J Vogt, Joern Dietrich, Sophia Loick, Ingela Grünwald, Marieta Toma, Carsten Golletz, Andreas Gerstner, Glen Kristiansen, Friedrich Bootz, Kathrin Scheckenbach, Jennifer Landsberg, Dimo Dietrich

EBioMedicine | Published : 2019

Abstract

BACKGROUND: The immune checkpoint, indoleamine 2,3-dioxygenase 1, is under investigation as target of novel immunotherapies for cancers, including head and neck squamous cell carcinomas (HNSCC). The aim of our study was to analyze DNA methylation of the encoding gene (IDO1) in HNSCC. METHODS: Methylation of three CpG sites within the promoter, promoter flank, and gene body was investigated and correlated with mRNA expression, immune cell infiltration, mutational burden, human papillomavirus (HPV)-status, and overall survival in a cohort of N = 528 HNSCC patients obtained from The Cancer Genome Atlas. In addition, IDO1 immunohistochemistry and DNA methylation analysis was performed in an inde..

View full abstract